J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):431-6.Szajewska H1, Albrecht P, Topczewska-Cabanek A.Author information12nd Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland. hania@ipgate.plAbstractOBJECTIVE: To determine the effectiveness of Lactobacillus GG (LGG) in children with Helicobacter pylori infection undergoing eradication therapy.MATERIALS AND METHODS: We conducted a double-blind, placebo-controlled, randomized trial comparing a 7-day, triple eradication regimen consisting of 2 antibiotics (amoxicillin tablets, 25 mg/kg twice per day, and clarithromycin tablets, 10 mg/kg twice per day) plus a proton pump inhibitor (omeprazole capsules, 0.5 mg/kg twice per day) supplemented with LGG (109 colony-forming units) or placebo in 83 children with H pylori infection confirmed by 2 of 3 tests (13C-urea breath test, histopathology, rapid urease test). The primary outcome measure was the H pylori eradication rate. The secondary outcome measure was the proportion of patients who experienced therapy-related adverse effects during anti-H pylori treatment.

RESULTS: The groups did not differ with respect to H pylori eradication rates. Of the 34 children in the LGG group, 23 (69%) experienced eradication, compared with 22 of 32 children (68%) in the placebo group (RR 0.98, 95% CI 0.7-1.4). The groups did not differ with respect to adverse effects.CONCLUSIONS: In children with H pylori infection, supplementation of standard triple therapy with LGG did not significantly alter the eradication rate or side effects.PMID: 19330931 [PubMed - indexed for MEDLINE] Publication TypesRandomized Controlled TrialMeSH TermsAdolescentAmoxicillin/adverse effectsAmoxicillin/therapeutic useAnti-Bacterial Agents/adverse effectsAnti-Bacterial Agents/therapeutic use*Anti-Ulcer Agents/adverse effectsAnti-Ulcer Agents/therapeutic use*ChildClarithromycin/adverse effectsClarithromycin/therapeutic useCombined Modality TherapyDietary SupplementsDouble-Blind MethodDrug Therapy, CombinationFemaleHelicobacter Infections/drug therapyHelicobacter Infections/microbiologyHelicobacter Infections/therapy*Helicobacter pylori*/drug effectsHumansLactobacillus*MaleOmeprazole/adverse effectsOmeprazole/therapeutic use*Placebos/therapeutic useProbiotics/therapeutic use*SubstancesAnti-Bacterial AgentsAnti-Ulcer AgentsPlacebosAmoxicillinClarithromycinOmeprazoleFull Text

SourcesLippincott Williams & WilkinsOvid Technologies, Inc.MedicalAntibiotics - MedlinePlus Health InformationHelicobacter Pylori Infections - MedlinePlus Health InformationMiscellaneousAMOXICILLIN - Hazardous Substances Data BankOMEPRAZOLE - Hazardous Substances Data BankClarithromycin - Hazardous Substances Data Bank2007 Jan 15;25(2):177-84.Gawrońska A1, Dziechciarz P, Horvath A, Szajewska H.Author information1Department of Paediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland.AbstractBACKGROUND: Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment.AIM: To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children.METHODS: A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks.

RESULTS: For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05-6.6, number needed to treat (NNT) 7, 95% CI: 4-123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2-38, NNT 4, 95% CI: 2-36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). How To Get A Ring Out Of Bathtub DrainFor the FD group (n = 20) and FAP group (n = 47), no differences were found.Curtains Martha StewartCONCLUSION: The LGG appears to moderately increase treatment success, particularly among children with IBS.House Movers Texas Inventory

PMID: 17229242 DOI: 10.1111/j.1365-2036.2006.03175.x [PubMed - indexed for MEDLINE] Publication TypesRandomized Controlled TrialResearch Support, Non-U.S. Gov'tMeSH TermsAbdominal Pain/diet therapy*AdolescentChildDouble-Blind MethodDyspepsia/diet therapy*FemaleHumansIrritable Bowel Syndrome/diet therapy*Lactobacillus rhamnosus*MaleProbiotics/therapeutic use*Treatment OutcomeFull Text SourcesWileyOvid Technologies, Inc.Other Literature SourcesSee the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. - Faculty of 1000MedicalClinicalTrials.govAbdominal Pain - MedlinePlus Health InformationIndigestion - MedlinePlus Health InformationMiscellaneousNCI CPTC Antibody Characterization ProgramHomeSeptember 2005 - Volume 11 - Issue 9 < Previous Abstract | Next Abstract > If you have access to this article through your institution, you can view this article in September 2005 - Volume 11 - Issue 9 - p 833–839 A Randomized, Double‐blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohn's Disease

Bousvaros, Athos MD, MPH1,*; Baldassano, Robert N MD3; Ferry, George D MD6; Murray, Karen F MD10; Rosh, Joel R MD12; Vanderhoof, Jon A MD14; Hibberd, Patricia L MD, PhD4 Probiotics are widely used by patients with Crohn's disease (CD) in an attempt to improve their health, but few controlled studies have been done to evaluate the efficacy of these therapies. We conducted a randomized, placebo‐controlled trial of the probiotic Lactobacillus rhamnosus strain GG (LGG) to see if the addition of LGG to standard therapy prolonged remission in children with CD. Concomitant medications allowed in the study included aminosalicylates, 6‐mercaptopurine, azathioprine, and low‐dose alternate day corticosteroids. Seventy‐five children (age range, 5‐21 yr) with CD in remission were randomized to either LGG (n = 39) or placebo (n = 36) and followed for up to 2 years. The median time to relapse was 9.8 months in the LGG group and 11.0 months in the placebo group (P = 0.24); 31% (12/39) of patients in the LGG group developed a relapse compared with 6/36 (17%) of the placebo group (P = 0.18).